
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Oral Paclitaxel for Patients with Advanced Solid Tumors
Details : INP12 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : INP20
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Immunotherapy for Peanut Allergic Patients
Details : INP20 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2019
Lead Product(s) : INP20
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
